美国多发性硬化女性妊娠及活产后的复发与疾病修正药物治疗
这项回顾性行政理赔数据库研究纳入2006年1月1日至2015年6月30日美国商业健康计划中多发性硬化(MS)并活产的女性2158例,评估孕前1年、妊娠期、产褥期(产后6周)及产后1年的复发与疾病修正药物(DMD)治疗。结果显示妊娠期复发几率下降(OR 0.623,95%CI 0.521-0.744;p<0.0001),产褥期升高(OR 1.710,95%CI 1.358-2.152;p<0.0001),产后最后3个季度末仍较高(OR 1.216,95%CI 1.052-1.406;p=0.0081)。DMD治疗整体偏低,孕前约20%,妊娠中期降至1.9%,产后9至12个月达25.5%。
要点
- 妊娠期MS复发几率较孕前下降(OR 0.623,95%CI 0.521-0.744;p<0.0001)。
- 产褥期复发几率较孕前升高(OR 1.710,95%CI 1.358-2.152;p<0.0001)。
- DMD治疗孕前约20%,妊娠中期降至1.9%,产后9至12个月达25.5%。
核心结论
- MS复发率妊娠期下降、产后6个月升高、产后6至12个月下降;DMD治疗孕前一年不常见,孕前即刻及妊娠期进一步减少,产后增加。
研究设计与样本
- 回顾性行政理赔数据库研究,使用2006年1月1日至2015年6月30日美国商业健康计划数据,纳入MS并活产女性2158例。
- 评估时间点为孕前1年、妊娠期、产褥期(产后6周)及产后1年;复发定义为MS相关住院、急诊就诊或门诊就诊且7天内开具皮质类固醇处方。
- 采用广义估计方程模型检验孕前与其他时间段的差异。
主要发现
- 妊娠期复发几率较孕前下降(OR 0.623,95%CI 0.521-0.744;p<0.0001)。
- 产褥期复发几率较孕前升高(OR 1.710,95%CI 1.358-2.152;p<0.0001)。
- 产后最后3个季度末复发几率仍高于孕前(OR 1.216,95%CI 1.052-1.406;p=0.0081)。
- DMD治疗比例孕前约20%,妊娠中期降至1.9%,产后9至12个月达25.5%;妊娠期较孕前下降(OR 0.171,95%CI 0.144-0.203;p<0.0001),产褥期仍较低(OR 0.361,95%CI 0.312-0.418;p<0.0001),产后最后3个季度末较高(OR 1.259,95%CI 1.156-1.371;p<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate relapse rates and disease-modifying drug (DMD) treatment in US women with multiple sclerosis (MS) and a live birth. METHODS: This retrospective administrative claims database study used US commercial health plan data from women with MS and a live birth from January 1, 2006, to June 30, 2015. Relapses and DMD treatment were evaluated 1-year prepregnancy, during pregnancy, during puerperium (6 weeks postpregnancy), and 1-year postpregnancy. Relapse was defined as MS-related hospitalization, emergency room visit, or outpatient visit with corticosteroid prescription within 7 days. Generalized estimating equation models for longitudinal data tested for differences between prepregnancy vs the other time periods. RESULTS: A total of 2,158 patients were eligible. The odds of relapse declined during pregnancy (odds ratio [OR] 0.623, 95% confidence interval [CI] 0.521-0.744; p < 0.0001), increased during puerperium (OR 1.710, 95% CI 1.358-2.152; p < 0.0001), and ended at a higher level during the last 3 postpartum quarters (OR 1.216, 95% CI 1.052-1.406; p = 0.0081). The proportion of women with DMD treatment was rather low overall: approximately 20% prepregnancy, bottoming to 1.9% during the second trimester, and peaking at 25.5% 9 to 12 months postpartum. DMD treatment declined significantly during pregnancy (OR 0.171, 95% CI 0.144-0.203; p < 0.0001), remained lower during puerperium (OR 0.361, 95% CI 0.312-0.418; p < 0.0001), and ended at a higher level during the last 3 postpartum quarters (OR 1.259, 95% CI 1.156-1.371; p < 0.0001). CONCLUSIONS: The rate of MS relapse decreased during pregnancy, increased 6 months postpartum, and decreased 6 to 12 months postpartum. DMD treatment was uncommon in the year before pregnancy, further decreased immediately prepregnancy and during pregnancy, and increased postpartum.
引用
- Houtchens MK, Edwards NC, Phillips AL, et al. Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology. 2018. PMID: 30266887. doi:10.1212/WNL.0000000000006382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。